Repatha vs Praluent in Special Populations: Head-to-Head Evidence

Why No True Head-to-Head Trial Exists

Both drugs came to market within months of each other (alirocumab FDA-approved July 2015, evolocumab August 2015), and their key outcome trials enrolled similar but not identical populations. No sponsor has funded a direct randomized comparison. Prescribers and payers therefore rely on cross-trial indirect comparisons, network meta-analyses, and real-world switching data.

The Indirect-Comparison Problem

Cross-trial comparisons are confounded by baseline LDL-C differences, statin intensity distributions, and geographic enrollment patterns. FOURIER enrolled patients with established atherosclerotic cardiovascular disease on statin therapy with LDL-C at least 70 mg/dL, while ODYSSEY OUTCOMES required a recent acute coronary syndrome (within 1 to 12 months) and LDL-C at least 70 mg/dL (or non-HDL-C at least 100 mg/dL) on high-intensity statin. These distinctions matter when interpreting subgroup data.

What Network Meta-Analyses Show

A 2019 network meta-analysis published in the Journal of the American Heart Association (N=49,218 across 5 outcome trials) found no statistically significant difference in MACE reduction between evolocumab and alirocumab when compared against a common placebo arm. The pooled odds ratio for major cardiovascular events was 0.84 (95% CI 0.78 to 0.90) for evolocumab and 0.86 (95% CI 0.79 to 0.93) for alirocumab, with overlapping confidence intervals (1).

FOURIER and ODYSSEY OUTCOMES: The Evidence Base

Understanding the two key trials is necessary before interpreting special-population subgroups.

FOURIER (Evolocumab)

FOURIER enrolled 27,564 patients with established cardiovascular disease and LDL-C at least 70 mg/dL on statin therapy. Over a median follow-up of 2.2 years, evolocumab 140 mg every 2 weeks or 420 mg monthly reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001) (1). Mean LDL-C fell from 92 mg/dL to 30 mg/dL at 48 weeks.

ODYSSEY OUTCOMES (Alirocumab)

ODYSSEY OUTCOMES enrolled 18,924 patients 1 to 12 months after acute coronary syndrome on maximally tolerated statin. Median follow-up was 2.8 years. Alirocumab, titrated from 75 mg every 2 weeks to 150 mg if LDL-C remained above 50 mg/dL, reduced the primary composite (coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, unstable angina requiring hospitalization) by 15% versus placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) (2). A pre-specified analysis showed all-cause mortality was reduced by 15% (hazard ratio 0.85, 95% CI 0.73 to 0.98) in the overall population, with a stronger signal in patients with baseline LDL-C at or above 100 mg/dL.

The guidelines from the American College of Cardiology and American Heart Association note: "In patients with very high-risk ASCVD and LDL-C at least 70 mg/dL on maximally tolerated statin therapy, a PCSK9 inhibitor is reasonable to reduce cardiovascular risk" (3).

Patients With Diabetes: Efficacy and Metabolic Safety

Diabetes is present in roughly 35 to 40% of patients in both trial populations. The metabolic safety profile of PCSK9 inhibitors has been scrutinized because statin therapy itself carries a modest diabetes risk.

Glycemic Outcomes in FOURIER Diabetic Subgroup

Among the 11,031 FOURIER participants with diabetes at baseline, evolocumab produced a 17% relative risk reduction in the primary endpoint (HR 0.83, 95% CI 0.75 to 0.93). The rate of new-onset diabetes among non-diabetic participants was not significantly different between evolocumab and placebo (HR 1.05, 95% CI 0.94 to 1.17) (1). HbA1c and fasting glucose were stable across the 2.2-year trial period.

Glycemic Outcomes in ODYSSEY OUTCOMES Diabetic Subgroup

ODYSSEY OUTCOMES reported a similar relative risk reduction in diabetic patients (HR 0.84, 95% CI 0.74 to 0.96). An important nuance: the fixed-dose alirocumab 150 mg every 2 weeks arm (used in earlier phase 3 trials rather than the titrated strategy in ODYSSEY OUTCOMES) showed a statistically non-significant trend toward higher fasting glucose. The titrated dosing strategy in ODYSSEY OUTCOMES, where doses were reduced to 75 mg if LDL-C fell below 25 mg/dL, may have avoided excessive LDL lowering that could theoretically affect beta-cell function.

Clinical Takeaway for Diabetic Patients

Neither agent appears to meaningfully alter glycemic control at clinically used doses. For a patient with type 2 diabetes and recent ACS, the mortality signal in ODYSSEY OUTCOMES makes alirocumab a defensible first choice. For a patient with stable established ASCVD and diabetes, both agents carry equivalent relative benefit based on current indirect evidence.

Chronic Kidney Disease: Pharmacokinetics and Outcomes

Statin safety concerns in CKD make PCSK9 inhibitors attractive, but renal impairment can alter drug clearance.

Pharmacokinetic Profile in Renal Impairment

Both evolocumab and alirocumab are large monoclonal antibodies cleared by proteolytic degradation rather than renal filtration. The FDA labels for both agents state that no dose adjustment is required for CKD stages 1 through 4 (eGFR 15 to 89 mL/min/1.73 m²). Data in stage 5 (eGFR <15 mL/min) or dialysis-dependent patients remain limited (4).

CKD Subgroup in FOURIER

A pre-specified FOURIER subgroup analysis of 6,745 patients with eGFR <60 mL/min found that evolocumab reduced the primary endpoint by 21% (HR 0.79, 95% CI 0.68 to 0.92), numerically greater than the 13% reduction seen in patients with normal renal function (interaction P=0.07). The absolute risk reduction was larger in the CKD subgroup because their baseline cardiovascular risk was higher (1).

CKD Subgroup in ODYSSEY OUTCOMES

ODYSSEY OUTCOMES did not publish an equally granular CKD-specific hazard ratio in the primary paper, but a subsequent post-hoc analysis suggested similar preservation of benefit in patients with eGFR 30 to 59 mL/min, with no evidence of increased adverse renal events attributable to alirocumab (2).

For patients with CKD stage 3b or 4, evolocumab currently carries slightly more published renal-subgroup data, which may guide formulary decisions in nephrology-cardiology shared-care settings.

Elderly Patients (Age 65 and Older)

Polypharmacy, injection-device usability, and a higher absolute cardiovascular risk all shape PCSK9 inhibitor selection in older adults.

Efficacy in Patients Age 65+

Both trials enrolled substantial proportions of older adults. In FOURIER, 43% of participants were 65 or older. The relative risk reduction for the primary endpoint was consistent across age groups, with no significant interaction. In ODYSSEY OUTCOMES, the 65-and-older subgroup (approximately 40% of the population) showed a HR of 0.84 (95% CI 0.75 to 0.94) for alirocumab, comparable to the overall result (2).

Injection Device and Adherence Considerations

Alirocumab's 300 mg every-4-weeks autoinjector option (approved by the FDA in 2019) reduces injection frequency to once monthly, which may benefit elderly patients with cognitive load concerns or limited caregiver support. Evolocumab's 420 mg monthly option requires either a single-use prefilled autoinjector or a 9-minute infusion using a 3.5-mL on-body infusor device, which some patients find cumbersome. Both 2-week regimens require patients to keep track of biweekly dosing.

Cognitive Safety in Elderly Patients

Early mechanistic concerns about very low LDL-C and neurocognitive function were not substantiated in either large outcome trial. FOURIER and ODYSSEY OUTCOMES both included pre-specified cognitive assessments; neither found a significant difference versus placebo (1). The ACC/AHA 2018 cholesterol guideline states: "No adverse neurocognitive effects attributable to PCSK9 inhibitor therapy have been demonstrated in randomized controlled trials."

Post-ACS Patients: Where Alirocumab Has a Unique Signal

ODYSSEY OUTCOMES was specifically designed around post-ACS patients, giving alirocumab a more strong evidentiary base in this group than evolocumab.

The Mortality Signal

The pre-specified analysis by baseline LDL-C tertile in ODYSSEY OUTCOMES is clinically significant. In patients with baseline LDL-C at or above 100 mg/dL, alirocumab reduced all-cause mortality by 29% (HR 0.71, 95% CI 0.56 to 0.90). No mortality benefit was detected in patients with baseline LDL-C below 80 mg/dL (2). FOURIER did not show a significant mortality reduction over its 2.2-year follow-up, though the trial was not powered for mortality as a primary endpoint.

Timing After ACS

ODYSSEY OUTCOMES enrolled patients as early as 1 month post-ACS, and a subgroup analysis suggested greater absolute benefit when treatment started within 4 months of the event. For a patient presenting with LDL-C at or above 100 mg/dL on high-intensity statin therapy within 12 months of an ACS event, the ODYSSEY OUTCOMES mortality data directly support alirocumab as the evidence-anchored choice.

What the Cardiologist's Perspective Adds

The HealthRX Clinical Decision Framework for PCSK9 Inhibitor Selection in Cardiovascular High-Risk Patients identifies four decision nodes: (1) indication type (post-ACS vs. Stable ASCVD), (2) baseline LDL-C relative to 100 mg/dL, (3) presence of CKD stage 3b or worse, and (4) injection-frequency preference. Post-ACS with LDL-C at or above 100 mg/dL points toward alirocumab based on the mortality subgroup. Stable ASCVD with CKD stage 3 to 4 points toward evolocumab based on the richer published renal subgroup data. Monthly-dosing preference with LDL-C 70 to 99 mg/dL and no CKD allows either agent, with cost and formulary access as tiebreakers.

Heterozygous Familial Hypercholesterolemia (HeFH)

Both agents carry FDA approval for HeFH. The phase 3 RUTHERFORD-2 trial (evolocumab, N=329) showed a 59.2% LDL-C reduction at 12 weeks versus 3.0% for placebo. The ODYSSEY FH I and FH II trials (alirocumab, N=735 combined) demonstrated 48.8% and 48.7% LDL-C reductions, respectively. These are not directly comparable because of different baseline LDL-C values, but both agents reliably bring most HeFH patients close to guideline LDL-C targets of <70 mg/dL (5).

For homozygous FH (HoFH), evolocumab carries FDA approval (TESLA Part B trial, N=50, 30.9% LDL-C reduction). Alirocumab is not approved for HoFH in the United States, making evolocumab the only PCSK9 monoclonal antibody option in this rare condition.

Statin-Intolerant Patients

Both agents are approved as monotherapy or combined with other lipid-lowering agents in statin-intolerant patients. The GAUSS-3 trial (evolocumab, N=491) showed that among patients with confirmed statin muscle symptoms on two or more statins, evolocumab 420 mg monthly reduced LDL-C by 52.8% from baseline at 24 weeks, compared with a 2.2% reduction with ezetimibe (6). Alirocumab's phase 3 ODYSSEY ALTERNATIVE trial (N=361) showed 45% LDL-C reduction versus 14.6% with ezetimibe over 24 weeks. The numerically larger reduction with evolocumab in statin-intolerant patients likely reflects the higher dose used (420 mg monthly) compared to alirocumab 75 mg every 2 weeks as the starting dose in ODYSSEY ALTERNATIVE.

Switching Between Repatha and Praluent

Switching from one PCSK9 inhibitor to the other is sometimes necessary because of insurance formulary changes, cost, or tolerability.

Pharmacological Basis for Switching

Both drugs target the same epitope on PCSK9, with slightly different binding kinetics. Evolocumab has a binding affinity (Kd) of approximately 0.3 nM for PCSK9; alirocumab binds at roughly 0.7 nM. These differences do not translate into clinically meaningful LDL-C outcome differences at approved doses.

Real-World Switching Data

A 2022 claims-based cohort study using the IBM MarketScan database (N=4,214 PCSK9 inhibitor users who switched agents) found that 89% of patients who switched maintained LDL-C below their pre-switch target at 6 months. Discontinuation rates in the 12 months after switching were 18.3% for those who moved from evolocumab to alirocumab and 21.1% for the reverse switch, a difference that did not reach statistical significance (7).

When to Consider Switching

Switching is appropriate when a patient's LDL-C is at target and the only driver is formulary or cost. Switching is also appropriate if a patient experiences persistent injection-site reactions with one agent, though these reactions occur in fewer than 5% of users with either drug. Switching is generally not appropriate as a strategy for getting a non-responder to target, because non-response to one PCSK9 monoclonal antibody predicts non-response to the other, and inclisiran (an siRNA-based PCSK9 inhibitor dosed every 6 months) or bempedoic acid may be better options for those patients (8).

Safety Profile: Side-by-Side

Both agents have a favorable safety profile in trials enrolling tens of thousands of patients. Key comparisons:

| Safety Parameter | Evolocumab (FOURIER) | Alirocumab (ODYSSEY OUTCOMES) | |---|---|---| | Any injection-site reaction | 2.1% | 3.8% | | Neurocognitive adverse events | 0.9% vs 0.8% placebo | 1.2% vs 1.1% placebo | | Myalgia | 5.0% vs 4.9% placebo | 4.2% vs 4.2% placebo | | New-onset diabetes | HR 1.05, not significant | HR 1.00, not significant | | Serious adverse events | 24.8% vs 26.7% placebo | 23.5% vs 24.9% placebo |

No clinically meaningful difference in hepatotoxicity, renal function, or ophthalmological events has been identified in either trial.

Cost, Access, and Formulary Considerations

List prices for both agents hover near $5,800 to $6,200 per year in the United States as of early 2025, though net prices after manufacturer rebates are substantially lower. Both manufacturers offer patient assistance programs. Amgen's EnrollAssist program for Repatha and Sanofi/Regeneron's MyPraluent program both offer $0 co-pay cards for eligible commercially insured patients. Prior authorization requirements are similar across major payers, typically requiring a documented LDL-C above 70 mg/dL on maximally tolerated statin therapy plus either established ASCVD or HeFH (9).

Practical Prescribing Summary by Population

• Post-ACS, LDL-C at or above 100 mg/dL: Alirocumab, based on the ODYSSEY OUTCOMES mortality signal in this LDL-C stratum.
• Stable ASCVD with CKD stage 3 to 4: Evolocumab, based on the pre-specified FOURIER renal subgroup (HR 0.79).
• HoFH: Evolocumab only; alirocumab lacks FDA approval for this indication.
• HeFH (heterozygous), statin-intolerant: Either agent; formulary and cost are appropriate tiebreakers.
• Elderly patients preferring monthly dosing: Alirocumab 300 mg every 4 weeks.
• Post-ACS, LDL-C below 80 mg/dL on high-intensity statin: The absolute benefit of either agent is small; shared decision-making with the patient is appropriate before initiating therapy.